{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T16:53:25Z","timestamp":1789750405604,"version":"4.0.1"},"reference-count":48,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Immune checkpoint inhibitors (ICIs) can cause adrenal insufficiency (AI) as an uncommon but potentially life-threatening immune-related adverse event (irAE). Early symptoms are often vague and may overlap with cancer-related fatigue or treatment side effects, contributing to diagnostic delays and under recognition.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We conducted a systematic review and meta-ethnographic synthesis of 64 published case reports (2015\u20132024) describing ICI-associated AI. Data on demographics, tumor type, ICI regimen, presenting symptoms, diagnostic process, hormonal and imaging findings, treatment, and outcomes were extracted. Narrative data were synthesized to explore contextual barriers to timely diagnosis. Quality assessment was performed using a modified CARE checklist.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Fatigue (67.2%), nausea (28.1%), appetite loss (25.0%), and hypotension (21.9%) were the most frequently reported symptoms. Notably, most patients (73.7%) presented with three or more concurrent symptoms, suggesting a pattern of symptom clustering that warrants clinical attention. Despite this, only 40.6% underwent dynamic endocrine testing, and pituitary imaging was frequently normal. Meta-ethnographic analysis revealed five recurrent themes underlying diagnostic delay: nonspecific symptomatology, low clinical suspicion, delayed hormonal testing, misleading imaging, and fragmented specialty care. Hospitalization occurred in 60.9% of cases, and glucocorticoid therapy was initiated in all. Recovery of adrenal function was rare (9.4%).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>ICI-related adrenal insufficiency often presents with multiple nonspecific symptoms that are easily misattributed, delaying diagnosis. Clinicians should maintain a high index of suspicion, particularly when multiple symptoms co-occur in ICI-treated patients, and initiate prompt endocrine evaluation. Standardized diagnostic pathways and interdisciplinary communication are essential to improve recognition and outcomes of this serious irAE.<\/jats:p><\/jats:sec><jats:sec><jats:title>Systematic review registration<\/jats:title><jats:p><jats:uri>https:\/\/www.crd.york.ac.uk\/PROSPERO\/view\/<\/jats:uri>, identifier CRD420251035850.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2025.1636452","type":"journal-article","created":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T04:18:15Z","timestamp":1759292295000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Initial symptoms and diagnostic delay in immune checkpoint inhibitor-related adrenal insufficiency: a systematic review and meta-ethnography of case reports"],"prefix":"10.3389","volume":"16","author":[{"given":"Ryuichi","family":"Ohta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinori","family":"Ryu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaoru","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiaki","family":"Sano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidetoshi","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-009742","article-title":"Systematic review of immune checkpoint inhibitor-related gastrointestinal, hepatobiliary, and pancreatic adverse events","volume":"12","author":"Shatila","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.2147\/cmar.S444916","article-title":"Immune-related adverse event-related adrenal insufficiency mediates immune checkpoint inhibitors efficacy in cancer treatment","volume":"16","author":"Zhang","year":"2024","journal-title":"Cancer Manag Res"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2023.11.003","article-title":"Primary adrenal insufficiency induced by immune checkpoint inhibitors: biological, clinical, and radiological aspects","volume":"50","author":"Martella","year":"2023","journal-title":"Semin Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj.EJ19-0163","article-title":"Management of immune-related adverse events in endocrine organs induced by immune checkpoint inhibitors: clinical guidelines of the Japan Endocrine Society","volume":"66","author":"Arima","year":"2019","journal-title":"Endocrine J"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2015-1710","article-title":"Diagnosis and treatment of primary adrenal insufficiency: an endocrine society clinical practice guideline","volume":"101","author":"Bornstein","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Matthew","year":"2021","journal-title":"BMJ"},{"key":"B9","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s12913-020-06049-w","article-title":"Meta-ethnography in healthcare research: a guide to using a meta-ethnographic approach for literature synthesis","volume":"21","author":"Sattar","year":"2021","journal-title":"BMC Health Serv Res"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1097\/00001888-200308000-00003","article-title":"The importance of cognitive errors in diagnosis and strategies to minimize them","volume":"78","author":"Croskerry","year":"2003","journal-title":"Acad Med"},{"key":"B11","doi-asserted-by":"publisher","first-page":"227.e221","DOI":"10.1016\/j.ajem.2024.04.046","article-title":"A case series of adrenal insufficiency (likely due to hypophysitis) in cancer patients treated with immune checkpoint inhibitors","volume":"80","author":"Yeung","year":"2024","journal-title":"Am J Emerg Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.4103\/jcrt.jcrt_831_21","article-title":"Hypophysitis: A rare but noteworthy immune-related adverse event secondary to camrelizumab therapy","volume":"18","author":"Han","year":"2022","journal-title":"J Cancer Res Ther"},{"key":"B13","doi-asserted-by":"publisher","first-page":"68","DOI":"10.55729\/2000-9666.1375","article-title":"Immunotherapy induced adrenal insufficiency: an underdiagnosed cause of persistent hypotension in cancer","volume":"14","author":"Cheng","year":"2024","journal-title":"J Community Hosp Intern Med Perspect"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jfma.2018.07.014","article-title":"Immune checkpoint inhibitor therapy-induced hypophysitis approximately a case series of Taiwanese patients","volume":"118","author":"Lin","year":"2019","journal-title":"J Formos Med Assoc"},{"key":"B15","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1530\/EDM-19-0102","article-title":"Clinical heterogeneity of hypophysitis secondary to PD-1\/PD-L1 blockade: insights from four cases","volume":"2019","author":"Lupi","year":"2019","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2019.102454","article-title":"Isolated autoimmune adrenocorticotropic hormone deficiency: From a rare disease to the dominant cause of adrenal insufficiency related to check point inhibitors","volume":"19","author":"Percik","year":"2020","journal-title":"Autoimmun Rev"},{"key":"B17","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1186\/s40425-019-0729-3","article-title":"Recovery from secondary adrenal insufficiency in a patient with immune checkpoint inhibitor therapy induced hypophysitis","volume":"7","author":"Thapi","year":"2019","journal-title":"J ImmunoTher Cancer"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e228135","DOI":"10.1136\/bcr-2018-228135","article-title":"Nivolumab-induced hypophysitis leading to hypopituitarism and secondary empty sella syndrome in a patient with non-small cell lung cancer","volume":"12","author":"Chang","year":"2019","journal-title":"BMJ Case Rep"},{"key":"B19","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s12902-019-0335-x","article-title":"Late-onset isolated adrenocorticotropic hormone deficiency caused by nivolumab: a case report","volume":"19","author":"Takeno","year":"2019","journal-title":"BMC Endocr Disord"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx497","article-title":"Two cases of late-onset secondary adrenal insufficiency after discontinuation of nivolumab","volume":"28","author":"Otsubo","year":"2017","journal-title":"Ann Oncol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"e931639","DOI":"10.12659\/AJCR.931639","article-title":"Isolated adrenocorticotropic hormone deficiency associated with severe hyperkalemia during pembrolizumab therapy in a patient with ureteral cancer and an ileal conduit: A case report and literature review","volume":"22","author":"Hinata","year":"2021","journal-title":"Am J Case Rep"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.9074-17","article-title":"Isolated adrenocorticotropin deficiency due to nivolumab-induced hypophysitis in a patient with advanced lung adenocarcinoma: A case report and literature review","volume":"57","author":"Ohara","year":"2018","journal-title":"Internal Med"},{"key":"B23","doi-asserted-by":"publisher","first-page":"34","DOI":"10.5582\/ddt.2023.01092","article-title":"PD-1\/PD-L1 inhibitors associated hypophysitis: An analysis from the FAERS database and case reports","volume":"18","author":"Chen","year":"2024","journal-title":"Drug Discov Ther"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1177\/23247096231194401","article-title":"Simultaneous presentation of secondary adrenal insufficiency and primary hypothyroidism due to pembrolizumab: A case report","volume":"11","author":"Khatri","year":"2023","journal-title":"J Invest Med High Impact Case Rep"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/s12328-021-01384-9","article-title":"Isolated adrenocorticotropic hormone deficiency induced by nivolumab treatment for advanced gastric cancer","volume":"14","author":"Namikawa","year":"2021","journal-title":"Clin J Gastroenterol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1186\/s12902-021-00854-y","article-title":"Late-onset hypophysitis after discontinuation of nivolumab treatment for advanced skin melanoma: a case report","volume":"21","author":"Antoniou","year":"2021","journal-title":"BMC Endocrine Disord"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2020.107050","article-title":"Reversible primary adrenal insufficiency related to anti-programmed cell-death 1 protein active immunotherapy: Insight into an unforeseen outcome of a rare immune-related adverse event","volume":"89","author":"Deligiorgi","year":"2020","journal-title":"Int Immunopharmacol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"e65163","DOI":"10.7759\/cureus.65163","article-title":"Secondary adrenal insufficiency as an immune-related adverse event of pembrolizumab therapy","volume":"16","author":"Esca\u00f1o","year":"2024","journal-title":"Cureus"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1080\/07435800.2020.1817064","article-title":"and ur E: primary and ipilimumab-induced hypophysitis: A single-center case series","volume":"45","author":"Atkins","year":"2020","journal-title":"Endocrine Res"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1210\/js.2017-00414","article-title":"Two cases of atezolizumab-induced hypophysitis","volume":"2","author":"Kanie","year":"2018","journal-title":"J Endocrine Soc"},{"key":"B31","doi-asserted-by":"publisher","first-page":"e41049","DOI":"10.7759\/cureus.41049","article-title":"Pembrolizumab-induced adrenal insufficiency presenting eight months after cessation of treatment","volume":"15","author":"Zilberman","year":"2023","journal-title":"Cureus"},{"key":"B32","article-title":"Secondary adrenal insufficiency following nivolumab therapy in a patient with metastatic renal cell carcinoma","volume":"42","author":"Seki","year":"2017","journal-title":"Tokai J Exp Clin Med"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj.EJ16-0161","article-title":"Nivolumab-induced hypophysitis in a patient with advanced Malignant melanoma","volume":"63","author":"Okano","year":"2016","journal-title":"Endocrine J"},{"key":"B34","doi-asserted-by":"publisher","first-page":"e7625","DOI":"10.7759\/cureus.7625","article-title":"Nivolumab induced adrenal insufficiency: rare side-effect of a new anti-cancer therapy - immune-checkpoint inhibitors","volume":"12","author":"Rai","year":"2020","journal-title":"Cureus"},{"key":"B35","doi-asserted-by":"publisher","first-page":"bcr-2018-225048","DOI":"10.1136\/bcr-2018-225048","article-title":"Delayed Presentation of Isolated Adrenocorticotropin Insufficiency after Nivolumab Therapy for Advanced Non-small-cell lung carcinoma (NSCLC)","volume":"2018","author":"Shrotriya","year":"2018","journal-title":"BMJ Case Rep"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.1446-22","article-title":"Isolated adrenocorticotropic hormone deficiency associated with atezolizumab and bevacizumab administration for treating hepatocellular carcinoma: A case series","volume":"62","author":"Ikeda","year":"2023","journal-title":"Internal Med"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1007\/s12328-023-01775-0","article-title":"Three cases of immune-related hypopituitarism after atezolizumab\u2013bevacizumab treatment for hepatocellular carcinoma","volume":"16","author":"Furuichi","year":"2023","journal-title":"Clin J Gastroenterol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"e243093","DOI":"10.1136\/bcr-2021-243093","article-title":"Abdominal pain as an initial symptom of isolated ACTH deficiency induced by nivolumab in a patient with Malignant mesothelioma","volume":"14","author":"Hata","year":"2021","journal-title":"BMJ Case Rep"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.8548-16","article-title":"Isolated adrenocorticotropic hormone deficiency caused by nivolumab in a patient with metastatic lung cancer","volume":"56","author":"Takaya","year":"2017","journal-title":"Internal Med"},{"key":"B40","doi-asserted-by":"publisher","first-page":"e8602","DOI":"10.7759\/cureus.8602","article-title":"A rare case of immune-mediated primary adrenal insufficiency with cytotoxic T-lymphocyte antigen-4 inhibitor ipilimumab in metastatic melanoma of lung and neck of unknown primary","volume":"12","author":"Gaballa","year":"2020","journal-title":"Cureus"},{"key":"B41","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1634\/theoncologist.2019-0555","article-title":"Immune checkpoint inhibitor-associated primary adrenal insufficiency: WHO vigiBase report analysis","volume":"25","author":"Grouthier","year":"2020","journal-title":"Oncologist"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1326684","article-title":"Immune checkpoint inhibitor-induced isolated adrenocorticotropic hormone deficiency: a systematic review","volume":"15","author":"Wang","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1159\/000507652","article-title":"Primary adrenal insufficiency during immune checkpoint inhibitor treatment: case reports and review of the literature","volume":"13","author":"Salinas","year":"2020","journal-title":"Case Rep Oncol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-008634","article-title":"Fluctuations in plasma adrenocorticotropic hormone concentration may predict the onset of immune checkpoint inhibitor-related hypophysitis","volume":"12","author":"Bando","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol29070370","article-title":"Routine screening for central and primary adrenal insufficiency during immune-checkpoint inhibitor therapy: an endocrinology perspective for oncologists","volume":"29","author":"Druce","year":"2022","journal-title":"Curr Oncol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1515\/cclm-2018-0824","article-title":"Central adrenal insufficiency: open issues regarding diagnosis and glucocorticoid treatment","volume":"57","author":"Ceccato","year":"2019","journal-title":"Clin Chem Lab Med"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2024.102734","article-title":"Endocrine-metabolic assessment checklist for cancer patients treated with immunotherapy: A proposal by the Italian Association of Medical Oncology (AIOM), Italian Association of Medical Diabetologists (AMD), Italian Society of Diabetology (SID), Italian Society of Endocrinology (SIE) and Italian Society of Pharmacology (SIF) multidisciplinary group","volume":"126","author":"Bando","year":"2024","journal-title":"Cancer Treat Rev"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Haanen","year":"2022","journal-title":"Ann Oncol"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1636452\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T04:18:16Z","timestamp":1759292296000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1636452\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,1]]},"references-count":48,"alternative-id":["10.3389\/fendo.2025.1636452"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2025.1636452","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,1]]},"article-number":"1636452"}}